Sequana Therapeutics and Boehringer Ingelheim form asthma research alliance.LA JOLLA La Jolla (lə hoi`yə), on the Pacific Ocean, S Calif., an uninc. district within the confines of San Diego; founded 1869. The beautiful ocean beaches, in particular La Jolla shores and Black's Beach, and sea-washed caves attract visitors and , Calif.--(BUSINESS WIRE)--June 14, 1995--Sequana Therapeutics Inc., based in La Jolla, Calif., and Boehringer Ingelheim, with headquarters in Ingelheim, Germany, today announced the signing of a collaborative research alliance aimed at identifying genetic causes of asthma and developing new therapeutics based on those findings. The new corporate alliance builds on a collaboration established last year between Sequana and the Samuel Lunenfeld Research Institute The Samuel Lunenfeld Research Institute of Mount Sinai Hospital (Toronto), Ontario, Canada was established in 1985 by an endowment from the Lunenfeld and Kunin families. It comprises 31 principal investigators, has a budget of C$90 million (2005/6), has 225 trainees and over 550 (SLRI SLRI Samuel Lunenfeld Research Institute (Toronto) ) of Mount Sinai Hospital Mount Sinai Hospital can refer to:
MSH abbr. melanocyte-stimulating hormone MSH, n See hormone, melanocyte-stimulating. MSH melanocyte-stimulating hormone. ) in Toronto, Canada, to isolate, clone and sequence genes associated with asthma. In connection with the signing of the agreement with Boehringer Ingelheim, Sequana will receive an equity investment of $6 million. During the research phase of the alliance, Sequana will receive license fees, research funding Research funding is a term generally covering any funding for scientific research, in the areas of both "hard" science and technology and social science. The term often connotes funding obtained through a competitive process, in which potential research projects are evaluated and and milestone payments which may total up to $32.5 million. In addition, Sequana will receive development milestone payments of up to $32 million upon the achievement of specific events. Boehringer Ingelheim will also pay to Sequana royalties on the sale of therapeutic products. In accordance with the agreement between Sequana and MSH, Sequana is obligated ob·li·gate tr.v. ob·li·gat·ed, ob·li·gat·ing, ob·li·gates 1. To bind, compel, or constrain by a social, legal, or moral tie. See Synonyms at force. 2. To cause to be grateful or indebted; oblige. to share with MSH and other Toronto institutions the license fees, milestone payments and royalties received from Boehringer Ingelheim. Sequana, SLRI and Boehringer Ingelheim will study the genetics of asthma, looking for Looking for In the context of general equities, this describing a buy interest in which a dealer is asked to offer stock, often involving a capital commitment. Antithesis of in touch with. insights into the molecular defects underlying the disease. Sequana researchers will focus on gene identification, while Boehringer Ingelheim focuses on gene expression and biology. Based on their findings, the companies will attempt to identify novel control points in the biochemistry of asthma that will lead to the development of innovative therapeutics and diagnostics for the disease and related conditions. Under the terms of the agreement, Boehringer Ingelheim gains exclusive rights to develop and commercialize therapeutic products based on genes discovered through the collaboration, while Sequana retains the rights to develop and commercialize diagnostic products. "We are very pleased to collaborate with Boehringer Ingelheim, a company that offers both outstanding capabilities in drug discovery and development and broad access to pharmaceutical markets world-wide," said Audrey D. Keane, vice president of business development at Sequana. "Boehringer Ingelheim's strong existing focus in asthma and other respiratory diseases, as well as their interest in developing innovative, next-generation treatments, makes them an ideal partner for this project." Professor Rolf Krebs, member of the board of managing directors of Boehringer Ingelheim and responsible for the Division Pharma pointed out that the cooperation with Sequana is focused on future-oriented research to find ways to prevent the development of inflammatory processes in the airways, and that this approach fits well with the research and development efforts of Boehringer Ingelheim in the field of respiratory diseases. The research collaboration begun by Sequana and SLRI in September 1994 employs blood samples and clinical data acquired by the Canadian researchers from the 300 closely related inhabitants
The game is based loosely on the concepts from SameGame. of Tristan da Cunha Tristan da Cunha (trĭs`tăn də k  `nə), group of volcanic islands in the S Atlantic, about midway between S Africa and S America. , an island in the South Atlantic belonging to the United Kingdom. These individuals exhibit one of the highest incidences of asthma in the world. Additional patient samples have been collected by SLRI and other Sequana collaborators throughout the world. Sequana was founded to discover and characterize the genes that cause or predispose pre·dis·pose v. To make susceptible, as to a disease. individuals to common diseases. Sequana has developed a proprietary gene discovery technology which is based on positional cloning, a method that uses statistical analysis of disease inheritance patterns to isolate disease genes. The company expects that identification of disease genes will provide insight into the causes of common diseases and facilitate the development of highly specific diagnostic and therapeutic products. Established in 1985, The Samuel Lunenfeld Research Institute of Mount Sinai Hospital, affiliated with the University of Toronto Research at the University of Toronto has been responsible for the world's first electronic heart pacemaker, artificial larynx, single-lung transplant, nerve transplant, artificial pancreas, chemical laser, G-suit, the first practical electron microscope, the first cloning of T-cells, , is widely recognized as one of Canada's premier biomedical research Biomedical research (or experimental medicine), in general simply known as medical research, is the basic research or applied research conducted to aid the body of knowledge in the field of medicine. facilities, with a research staff of over 380. The Institute has recently announced the establishment of a new Centre for Human Genome Research and Molecular Medicine focusing on polygenic diseases. Boehringer Ingelheim is an international corporation with headquarters in Ingelheim, Germany, operating in the fields of pharmaceutical, biological, and chemical products. With about 160 companies, the Boehringer Ingelheim corporation is represented on every continent. With its own research, production and distribution facilities, it ranks among the 20 major pharmaceutical companies worldwide. CONTACT: Sequana Therapeutics, La Jolla Audrey D. Keane, 619/452-6550 or J. Kureczka Associates Joan Kureczka, 415/821-2413 or Boehringer Ingelheim GmbH Judith v. Gordon, +49 6132 773582, fax, +49 6132 776601 or For inquiries within the United States: Boehringer Ingelheim Pharmaceuticals Inc. Pam DeMala, 203/798-4700 |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion